PARP Inhibitors in Ovarian Cancer: Sensitivity Prediction and Resistance Mechanisms

Journal of Cellular and Molecular Medicine - United Kingdom
doi 10.1111/jcmm.14133
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

PARP Inhibitors in Ovarian Cancer

2013English

Extending the Scope of PARP Inhibitors in Ovarian Cancer

The Lancet Oncology
Oncology
2019English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

The Development of PARP Inhibitors in Ovarian Cancer: From Bench to Bedside

British Journal of Cancer
Cancer ResearchOncology
2015English

A Unique Subset of Epithelial Ovarian Cancers With Platinum Sensitivity and PARP Inhibitor Resistance

Cancer Research
Cancer ResearchOncology
2015English

Layer‐by‐Layer Nanoparticles for Novel Delivery of Cisplatin and PARP Inhibitors for Platinum‐Based Drug Resistance Therapy in Ovarian Cancer

Bioengineering & Translational Medicine
2019English

PARP Inhibitor Treatment in Ovarian and Breast Cancer

Current Problems in Cancer
Cancer ResearchOncology
2011English

PARP Inhibitors for BRCA1/2-mutated and Sporadic Ovarian Cancer: Current Practice and Future Directions

British Journal of Cancer
Cancer ResearchOncology
2016English

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Cancer Cell
Cancer ResearchOncologyCell Biology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy